Mealey's (October 4, 2018, 12:33 PM EDT) -- TRENTON, N.J. — The New Jersey Supreme Court on Oct. 3 said that New Jersey law applies to 532 state court Accutane bowel injury cases and that the plaintiffs’ cases must be dismissed because the acne drug’s label adequately warned of the risk of inflammatory bowel disease (IBD) under New Jersey’s product liability law (In Re: Accutane Litigation, No. A-26/27 September Term 2017, 079933, N.J. Sup., 2018 N.J. LEXIS 1187)....